Stop the bleeding: Idarucizumab als Dabigatran-Antidot vor der Zulassung

Author: WagnerBianca   HelmstädterMoritz   StierleSina   UebbingLukas   EbertRoland   PekniceManuel   ZündorfIlse   DingermannTheo   FürstRobert  

Publisher: Govi-Verlag

ISSN: 2195-2175

Source: PHARMAKON, Vol.3, Iss.5, 2015-09, pp. : 332-334

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract